ISSN: 2960-1959
Publisher
Review Articles

Post COVID-19 Pulmonary Fibrosis Management: A Systematic Review

Hamdi Yahya Al Turkey
Faculty of Medicine, Taiz University, Taiz City, Yemen
Aland S. Abdullah
College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
Harem K. Ahmed
Shar Teaching Hospital, Sulaymaniyah, Kurdistan, Iraq
Bnar J. Hama Amin
Shar Teaching Hospital, Sulaymaniyah, Kurdistan, Iraq
Yousif M. Mahmood
Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
Suhaib H. Kakamad
Department of Immunology and Hematology, College of Medicine, Kurdistan University of Medical Science, Sanandaj, Iran
Aso N. Qadir
Smart Health Tower/Raparin, Rania, Sulaymaniyah, Kurdistan, Iraq
Hemin S. Mohammed
Kalar General Hospital, Kalar, Sulaymaniyah, Kurdistan, Iraq
Hemn H. Bayz
Smart Health Tower/Raparin, Rania, Sulaymaniyah, Kurdistan, Iraq
Shevan M. Mustafa
Kscien Organization for Scientific Research (Middle East office), Hamid Street, Azadi Mall, Sulaymaniyah, Kurdistan, Iraq
Sanaa O. Karim
College of Nursing, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
Hawbash M. Rahim
Medical Laboratory Science Department, College of Health Sciences, University of Human Development, Sulaymaniyah, Kurdistan Region, Iraq
Berun A. Abdalla
Department of Biology, College of Education, University of Sulaimani, Sulaymaniyah, Kurdistan, Iraq
Fahmi H. Kakamad
College of Medicine, University of Sulaimani, Madam Mitterrand Street, Sulaymaniyah, Kurdistan, Iraq
Abstract
266
Downloads
115
Published: March 2, 2024
PDF
PDF

Abstract

Introduction

Post-COVID-19 Pulmonary Fibrosis (PC-19-PF) is among the complications following COVID-19. It is the complication that is associated with the most amount of long-term impact on the respiratory system. Different physicians approach management in different ways; therefore, we conduct a study to neatly summarize all the different management and their possible outcomes.

Methods

The databases that were searched included CINAHL, PubMed/MEDLINE, Cochrane Library, Web of Science, and EMBASE to identify English language studies published up to October 5th, 2023.

Results

Initially, the systematic search conducted brought 150 papers. Out of the 150, 13 of them were included in this study. A total of 662 patients were included in the study, all with different managements for COVID-19-induced pulmonary fibrosis. The mean age was 61.8 years. Many comorbidities were observed in patients with COVID-19-induced pulmonary fibrosis. Different treatment regimens were picked based on the different conditions of the patients but as far as antifibrotics go, Pirfenidone and Nintedanib were the most commonly used ones.

Conclusion

Both antifibrotics and steroids seemed to yield justifiable outcomes when used separately as well as when used in combination.

References

  1. Stuart A. Benign Tumors: Types, Causes, and Treatments [Internet]. WebMD. Available from: https://www.webmd.com/a-to-z-guides/benign-tumors-causestreatments#:~:text=Treatment%20of%20Benign%20Tumors
  2. Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. Journal of Zhejiang University. Science. B. 2020; 21(5):343. doi:10.1631/jzus.B2000083
  3. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine. 2020; 382(8):727-33. doi:10.1056/NEJMoa2001017
  4. World Health Organization: WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) [Internet]. Who.int. World Health Organization: WHO; 2020. Available from: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)
  5. World Health Organization. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 - 11 March 2020 [Internet]. World Health Organization. 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
  6. WHO. WHO COVID-19 dashboard [Internet]. World Health Organization. 2023. Available from: https://covid19.who.int/
  7. Mehraeen E, Salehi MA, Behnezhad F, Moghaddam HR, SeyedAlinaghi S. Transmission modes of COVID-19: a systematic review. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders). 2021; 21(6):27-34. doi:10.2174/1871526520666201116095934
  8. Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. Journal of preventive medicine and hygiene. 2020; 61(3):E304. doi:10.15167/2421-4248/jpmh2020.61.3.1530
  9. Noor AU, Maqbool F, Bhatti ZA, Khan AU. Epidemiology of CoViD-19 Pandemic: Recovery and mortality ratio around the globe. Pakistan journal of medical sciences. 2020; 36(COVID19-S4): S79. doi:10.12669/pjms.36.COVID19-S4.2660
  10. Chippa V, Aleem A, Anjum F. Post acute coronavirus (COVID-19) syndrome. doi:N/A
  11. Duong-Quy S, Vo-Pham-Minh T, Tran-Xuan Q, Huynh-Anh T, Vo-Van T, Vu-Tran-Thien Q, et al. post-COVID-19 Pulmonary Fibrosis: Facts—Challenges and Futures: A Narrative Review. Pulmonary Therapy. 2023; 20:1-3. doi:10.1007/s41030-023-00226-y
  12. Kooistra EJ, Dahm K, van Herwaarden AE, Gerretsen J, Nuesch Germano M, Mauer K, et al. Molecular mechanisms and treatment responses of pulmonary fibrosis in severe COVID-19. Respiratory Research. 2023; 24(1):196. doi:10.1186/s12931-023-02496-1
  13. Zhou X, Yang D, Kong X, Wei C, LvQiu S, Wang L, et al. Case report: pirfenidone in the treatment of post-COVID-19 pulmonary fibrosis. Frontiers in medicine. 2022; 9:925703. doi:10.3389/fmed.2022.925703
  14. Singh P, Behera D, Gupta S, Deep A, Priyadarshini S, Padhan P. Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: A single-centre study. Journal of the Royal College of Physicians of Edinburgh. 2022; 52(2):100-4. doi:10.1177/14782715221103402
  15. Lomanta JM, Quinto ML, Urquiza SC, Santiaguel JM. Pulmonary function and chest computed tomography (CT) scan findings after antifibrotic treatment for COVID-19-related pulmonary fibrosis. The American Journal of Case Reports. 2022;23: e934830-1. doi:10.12659/AJCR.934830
  16. Uemasu K, Yasuda Y, Hirayama Y, Arasawa S, Iwashima D, Takahashi KI. Post-COVID-19 interstitial lung disease presenting with profound hypoxemia: Report of three cases demonstrating a good response to high-dose corticosteroid therapy. Journal of Infection and Chemotherapy. 2022; 28(2):321-5. doi:10.1016/j.jiac.2021.11.010
  17. Günay S, Parlak İS, Hezer H, Parlak EŞ, Umut MS, Hancıoğlu Z, et al. Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases. 2023;40(3). doi:10.36141/svdld.v40i3.14418
  18. Wu J, Zhou X, Tan Y, Wang L, Li T, Li Z, et al. Phase 1 trial for treatment of COVID‐19 patients with pulmonary fibrosis using hESC‐IMRCs. Cell proliferation. 2020; 53(12):e12944. doi:10.1111/cpr.12944
  19. Vitug LC, Santiaguel J. Nintedanib as an adjunct treatment in improving lung function of post-COVID-19 pulmonary fibrosis in an elderly patient: a case report. Chest. 2021 Oct 1;160(4): A2166. doi:10.1016/j.chest.2021.07.1914
  20. Udwadia ZF, Pawar UP, Nanda VJ. Severe interstitial lung disease persisting 2 years post-COVID-19 despite anti-fibrotic therapy. Lung India: Official Organ of Indian Chest Society. 2022; 39(6):587. doi:10.4103/lungindia.lungindia_355_22
  21. He JW, Su Y, Qiu ZS, Wu JJ, Chen J, Luo Z, et al. Steroids Therapy in Patients With Severe COVID-19: Association With Decreasing of Pneumonia Fibrotic Tissue Volume. Frontiers in medicine. 2022; 9:907727. doi:10.3389/fmed.2022.907727
  22. Uyar BS, Ensarioğlu K, Kurt EB, Özkan D, Güneş SÖ. Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation. Turkish Journal of Anaesthesiology and Reanimation. 2022; 50(3):228. doi:10.5152%2FTJAR.2021.20450
  23. Kotfis K, Karolak I, Lechowicz K, Zegan-Barańska M, Pikulska A, Niedźwiedzka-Rystwej P, et al. Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis—A Randomized Placebo Controlled Clinical Trial. Pharmaceuticals. 2022; 15(2):200. doi:10.3390/ph15020200
  24. Chen JY, Qiao K, Liu F, Wu B, Xu X, Jiao GQ, et al. Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis. Chinese medical journal. 2020; 133(12):1390-6. doi:10.1097/CM9.0000000000000839
  25. Woo PC, Huang Y, Lau SK, Yuen KY. Coronavirus genomics and bioinformatics analysis. viruses. 201; 2(8):1804-20. doi:10.3390/v2081803
  26. Abebe EC, Dejenie TA, Shiferaw MY, Malik T. The newly emerged COVID-19 disease: a systemic review. Virology journal. 2020; 17(1):1-8. doi:10.1186/s12985-020-01363-5
  27. Henkens MT, Raafs AG, Verdonschot JA, Linschoten M, Van Smeden M, Wang P, et al. Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study. BMC geriatrics. 2022; 22(1):1-1. doi:10.1186/s12877-021-02673-1
  28. Mayo Clinic. COVID-19: Who’s at higher risk of serious symptoms? [Internet]. Mayo Clinic. 2022. Available from: https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-who-is-at-risk/art-20483301#:~:text=Older%20age
  29. WHO. Coronavirus disease (COVID-19) [Internet]. www.who.int. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/coronavirus-disease-(covid-19)
  30. Singh MK, Mobeen A, Chandra A, Joshi S, Ramachandran S. A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?. Computers in Biology and Medicine. 2021; 130:104219. doi:10.1016/j.compbiomed.2021.104219
  31. Silaghi-Dumitrescu R, Patrascu I, Lehene M, Bercea I. Comorbidities of COVID-19 Patients. Medicina. 2023; 59(8):1393. doi:10.3390/medicina59081393
  32. Li W, Wang D, Guo J, Yuan G, Yang Z, Gale RP, et al. COVID-19 in persons with chronic myeloid leukaemia. Leukemia. 2020; 34(7):1799-804. doi:10.1038/s41375-020-0853-6
  33. Djaharuddin I, Munawwarah S, Nurulita A, Ilyas M, Tabri NA, Lihawa N. Comorbidities and mortality in COVID-19 patients. Gaceta sanitaria. 2021; 35: S530-2. doi:10.1016/j.gaceta.2021.10.085
  34. John KJ, Nayar J, Mishra AK, Selvaraj V, Khan MS, Lal A. In-hospital clinical complications of COVID-19: a brief overview. Future Virology. 2021; 16(11):717-23. doi:10.2217/fvl-2021-0200
  35. Jakubec P, Fišerová K, Genzor S, Kolář M. Pulmonary complications after COVID-19. Life. 2022; 12(3):357. doi:10.3390/life12030357
  36. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA network open. 2021; 4(10):e2128568-. doi:10.1001/jamanetworkopen.2021.28568
  37. Tanni SE, Fabro AT, de Albuquerque A, Ferreira EV, Verrastro CG, Sawamura MV, et al. Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert review of respiratory medicine. 2021; 15(6):791-803. doi:10.1080/17476348.2021.1916472
  38. Amin BJ, Kakamad FH, Ahmed GS, Ahmed SF, Abdulla BA, Mikael TM, et al. Post COVID-19 pulmonary fibrosis; a meta-analysis study. Annals of Medicine and Surgery. 2022; 77:103590. doi:10.1016/j.amsu.2022.103590
  39. Tran S, Ksajikian A, Overbey J, Li P, Li Y. Pathophysiology of Pulmonary Fibrosis in the Context of COVID-19 and Implications for Treatment: A Narrative Review. Cells. 2022; 11(16):2489. doi:10.3390/cells11162489
  40. Duong-Quy S, Vo-Pham-Minh T, Tran-Xuan Q, Huynh-Anh T, Vo-Van T, Vu-Tran-Thien Q, et al. Post-COVID-19 Pulmonary Fibrosis: Facts—Challenges and Futures: A Narrative Review. Pulmonary Therapy. 2023: 1-3. doi:10.1007/s41030-023-00226-y
  41. Al-Kuraishy HM, Batiha GE, Faidah H, Al-Gareeb AI, Saad HM, Simal-Gandara J. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology. 2022; 30(6):2017-26. doi:10.1007/s10787-022-01027-6
  42. Lam E, Sayedy N, Anjum F, Akella J, Iqbal J. Corticosteroid therapy in post-COVID-19 pulmonary fibrosis. InTP47. TP047 COVID AND ARDS CASE REPORTS 2021 May (pp. A2429-A2429). American Thoracic Society. doi:N/A

Similar Articles

You may also start an advanced similarity search for this article.

Keywords
Copyright (c) 2024 Barw Medical Journal Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Send mail to Author

Send Cancel
Copyright© Barw Publications 2023. All rights reserved
Themes by Openjournaltheme.com